Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC PR...
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.